<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01320033</url>
  </required_header>
  <id_info>
    <org_study_id>RD.06.SPR.18195</org_study_id>
    <nct_id>NCT01320033</nct_id>
  </id_info>
  <brief_title>Placebo Controlled Efficacy and Safety Study of CD2475/101 40 mg Tablets vs. Placebo and Doxycycline 100 mg Capsules Once Daily in the Treatment of Inflammatory Lesions of Acne Vulgaris</brief_title>
  <official_title>A Multi Center, Randomized, Double Blind, Placebo Controlled, 3 Arm, Parallel Group Study Comparing the Efficacy and Safety of CD2475/101 40 mg Tablets Versus Placebo and Doxycycline 100 mg Capsules Once Daily in the Treatment of Inflammatory Lesions in Subjects With Acne Vulgaris</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Galderma</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Galderma</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objectives of the study is to show CD2475/101 40mg tablets taken once a day for
      16 weeks is superior to the placebo in Change from baseline to Week 16(Last Observation Carry
      Forward, Intent To Treat) in inflammatory lesion counts.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Investigator's global assessment and lesion count will be performed at each study visit.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 29, 2011</start_date>
  <completion_date type="Actual">January 3, 2012</completion_date>
  <primary_completion_date type="Actual">January 3, 2012</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change From Baseline in Inflammatory Lesion Counts to Week 16 (Last Observation Carried Forward [LOCF])</measure>
    <time_frame>From Baseline up to Week 16 (LOCF)</time_frame>
    <description>The Inflammatory lesion count was the count of papules and pustules: papule was a small, solid elevation less than 0.5 cm in diameter, pustule was a small, circumscribed elevation of the skin that contains yellow-white exudate. Change from baseline in inflammatory lesion counts to Week 16 (LOCF) were reported.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Investigator Global Assessment (IGA) Success Rate at Week 16 (Last Observation Carried Forward [LOCF])</measure>
    <time_frame>Week 16 (LOCF)</time_frame>
    <description>IGA scale consisted of 5 grades (0-4) among which 0= Clear (no evidence of papules or pustules [inflammatory lesions]), 1= Almost clear (rare non-inflamed papules (papules must be resolving and hyperpigmented, though not pink-red), 2= Mild (few inflammatory lesions [papules/pustules only; no nodulo-cystic lesions]), 3=Moderate (multiple inflammatory lesions evident: many papules/pustules; up to two nodulocystic lesions), 4= Severe (inflammatory lesions are more apparent, many papules/pustules, few nodulo-cystic lesions). Success rate was defined as percentage of participants who achieved an Investigator Global Assessment (IGA) score of 1 (almost clear) or 0 (Clear) and at least a 2-grade improvement from Baseline to Week 16 (LOCF).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline in Inflammatory Lesion Counts to Week 16 (Last Observation Carried Forward [LOCF])</measure>
    <time_frame>From Baseline up to Week 16 (LOCF)</time_frame>
    <description>The Inflammatory lesion count was the count of papules and pustules: papule was a small, solid elevation less than 0.5 cm in diameter, pustule was a small, circumscribed elevation of the skin that contains yellow-white exudate. Percent change from baseline in inflammatory lesion counts to Week 16 (LOCF) were reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline in Total Lesion Counts to Week 16 (Last Observation Carried Forward [LOCF])</measure>
    <time_frame>From Baseline up to Week 16 (LOCF)</time_frame>
    <description>Total lesions were the sum of inflammatory lesion counts, non-inflammatory lesion counts, nodules and cysts. Percentage change from baseline in total lesion counts to Week 16 were reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Non-Inflammatory Lesion Counts to Week 16 (Last Observation Carried Forward [LOCF])</measure>
    <time_frame>From Baseline up to Week 16 (LOCF)</time_frame>
    <description>The non-inflammatory lesion count was the count of open and closed comedones: Open comedone was a pigmented dilated pilosebaceous orifice (blackhead). Closed comedone was a tiny white papule (whitehead). Change from baseline in non-inflammatory lesion counts to week 16 were reported</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Global Assessment for Inflammatory Lesions of Truncal Acne at Baseline, Week 12, and Week 16</measure>
    <time_frame>Baseline, Week 12, and Week 16</time_frame>
    <description>Global assessments for inflammatory lesions of truncal acne were done separately on back and chest. The global assessments severity scale included 5 grades (0-4): where in 0= Clear-no evidence of papules or pustules (inflammatory lesions), 1= Almost clear- rare non-inflamed papules (papules must be resolving and may be hyperpigmented, though not pink-red), 2=Mild- few inflammatory lesions (papules/pustules only; no nodulo-cystic lesions), 3=Moderate- multiple inflammatory lesions evident: many papules/pustules; may be a few nodulocystic lesions, 4=Severe- inflammatory lesions are more apparent, many papules/pustules, may be a few nodulo-cystic lesions.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With at Least One Adverse Event (AE)</measure>
    <time_frame>From Baseline up to Week 16</time_frame>
    <description>An AE was any untoward medical occurrence in a participant or clinical investigation participants administered a pharmaceutical product and which does not necessarily have a causal relationship with this treatment. Number of participants with at least one AE were reported.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">662</enrollment>
  <condition>Acne Vulgaris</condition>
  <arm_group>
    <arm_group_label>CD2475/101 40 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants receive 40 mg of CD2475/101 oral tablet plus placebo capsule orally once daily for 16 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Doxycycline 100 mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants receive 100 mg of Doxycycline capsule plus placebo tablet orally once daily for 16 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants receive matching placebo tablet plus placebo capsule orally once daily for 16 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CD2475/101 40 mg</intervention_name>
    <description>Participants receive 40 mg of CD2475/101 tablets once a day for 16 weeks.</description>
    <arm_group_label>CD2475/101 40 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Doxycycline 100 mg</intervention_name>
    <description>Participants receive 100 mg of Doxycycline capsule once a day for 16 weeks</description>
    <arm_group_label>Doxycycline 100 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Participants receive matching placebo tablet, matching placebo capsule once a day for 16 weeks.</description>
    <arm_group_label>CD2475/101 40 mg</arm_group_label>
    <arm_group_label>Doxycycline 100 mg</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male and female subjects 12 years of age or older

          -  acne vulgaris with facial involvement

          -  A score of 3 (Moderate) or 4 (Severe) on the Investigator's Global Assessment Scale
             (inflammatory)

          -  25 to 75 inflammatory lesions (papules and pustules) on the face (including the nose)

        Exclusion Criteria:

          -  More than two acne nodules/cysts on the face

          -  Acne conglobata, acne fulminans, secondary acne (chloracne, drug induced acne, etc.),
             or severe acne requiring systemic retinoid treatment

          -  Underlying diseases or other dermatologic conditions that require the use of
             interfering topical or systemic therapy such as, but not limited to, atopic
             dermatitis, perioral dermatitis or rosacea

          -  Beard or facial hair which might interfere with study assessments

          -  planning excessive exposure to sun or ultraviolet light during the study (i.e. natural
             or artificial sunlight, including tanning booths and sun lamp)

          -  Use of oral contraceptives solely for control of acne

          -  Liver function test alanine transaminase (ALT) and/or aspartate transaminase (AST) 2.5
             times above upper limit of normal

          -  Renal function test serum creatinine at 150 umol/L (17 mg/L) or higher

          -  Presence of oral or genital candidiasis or history of multiple episodes of oral or
             genital candidiasis

          -  Females who intend to conceive a child within 5 months following Baseline visit

          -  Males who intend to conceive a child with partner during the study period

          -  Requiring concomitant use of methoxyflurane
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michael Graeber, MD</last_name>
    <role>Study Director</role>
    <affiliation>Galderma</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Burke Pharmaceutical Research</name>
      <address>
        <city>Hot Springs</city>
        <state>Arkansas</state>
        <zip>71913</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dermatology Research Associates, Inc.</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90045</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Colorado Medical Research Center</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Longmont Medical Research Network</name>
      <address>
        <city>Longmont</city>
        <state>Colorado</state>
        <zip>80501</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>International Dermatology Research, Inc.</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33144</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MedaPhase, Inc.</name>
      <address>
        <city>Newnan</city>
        <state>Georgia</state>
        <zip>30263</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dermatology Specialists PC</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Somerset Skin Care Center</name>
      <address>
        <city>Troy</city>
        <state>Michigan</state>
        <zip>48084</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Grekin Skin Care</name>
      <address>
        <city>Warren</city>
        <state>Michigan</state>
        <zip>48088</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Central Dermatology, PC</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63117</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Skin Specialists, PC</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68144</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Academic Dermatology</name>
      <address>
        <city>Albuquerque</city>
        <state>New Mexico</state>
        <zip>87106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Helendale Dermatology &amp; Medical Spa</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14609</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dermatology Consulting Services</name>
      <address>
        <city>High Point</city>
        <state>North Carolina</state>
        <zip>27262</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>PMG Research of Wilmington</name>
      <address>
        <city>Wilmington</city>
        <state>North Carolina</state>
        <zip>28401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Haber Dermatology &amp; cosmetic Surgery, Inc</name>
      <address>
        <city>South Euclid</city>
        <state>Ohio</state>
        <zip>44118</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Central Sooner Research</name>
      <address>
        <city>Norman</city>
        <state>Oklahoma</state>
        <zip>73069</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oregon Dermatology &amp; Research Center</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Stephen Schleicher</name>
      <address>
        <city>Hazleton</city>
        <state>Pennsylvania</state>
        <zip>18201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Palmetto Clinical Trial Services, LLC</name>
      <address>
        <city>Greenville</city>
        <state>South Carolina</state>
        <zip>29607</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dermatology Research Associates</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37203</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tennessee Clinical Research Center</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Arlington Center for Dermatology</name>
      <address>
        <city>Arlington</city>
        <state>Texas</state>
        <zip>76011</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Derm Research, Inc</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78759</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>J&amp;S Studies</name>
      <address>
        <city>College Station</city>
        <state>Texas</state>
        <zip>77845</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Suzanne Bruce and associates P.A. The Center for skin Research</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77056</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Center for Clinical Studies</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77058</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Progressive Clinical Research</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Stephen Miller MD</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dermatology Research Center</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84124</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Premier Clinical Research</name>
      <address>
        <city>Spokane</city>
        <state>Washington</state>
        <zip>99204</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2019</verification_date>
  <study_first_submitted>March 21, 2011</study_first_submitted>
  <study_first_submitted_qc>March 21, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 22, 2011</study_first_posted>
  <results_first_submitted>November 21, 2019</results_first_submitted>
  <results_first_submitted_qc>February 6, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">February 10, 2020</results_first_posted>
  <last_update_submitted>February 6, 2020</last_update_submitted>
  <last_update_submitted_qc>February 6, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 10, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>acne vulgaris</keyword>
  <keyword>inflammatory lesions</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acne Vulgaris</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Doxycycline</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>This study was conducted in United States between 29 March 2011 (first participant first visit) to 3 January 2012 (last participant last visit).</recruitment_details>
      <pre_assignment_details>A total of 662 participants randomized the study and dispensed with study drug out of which 487 completed study.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>CD2475/101 40 mg</title>
          <description>Participants received 40 milligrams (mg) of CD2475/101 oral tablet plus placebo capsule orally once daily for 16 weeks.</description>
        </group>
        <group group_id="P2">
          <title>Doxycycline 100 mg</title>
          <description>Participants received 100 mg of Doxycycline capsule plus placebo tablet orally once daily for 16 weeks.</description>
        </group>
        <group group_id="P3">
          <title>Placebo</title>
          <description>Participants received matching placebo tablet plus placebo capsule orally once daily for 16 weeks.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="216"/>
                <participants group_id="P2" count="224"/>
                <participants group_id="P3" count="222"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="158"/>
                <participants group_id="P2" count="160"/>
                <participants group_id="P3" count="169"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="58"/>
                <participants group_id="P2" count="64"/>
                <participants group_id="P3" count="53"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="7"/>
                <participants group_id="P3" count="8"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="22"/>
                <participants group_id="P2" count="23"/>
                <participants group_id="P3" count="23"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="22"/>
                <participants group_id="P2" count="26"/>
                <participants group_id="P3" count="17"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Intent-to-treat (ITT) Population consisted of all participants who were randomized and to whom study drug was dispensed.</population>
      <group_list>
        <group group_id="B1">
          <title>CD2475/101 40 mg</title>
          <description>Participants received 40 mg of CD2475/101 oral tablet plus placebo capsule orally once daily for 16 weeks.</description>
        </group>
        <group group_id="B2">
          <title>Doxycycline 100 mg</title>
          <description>Participants received 100 mg of Doxycycline capsule plus placebo tablet orally once daily for 16 weeks.</description>
        </group>
        <group group_id="B3">
          <title>Placebo</title>
          <description>Participants received matching placebo tablet plus placebo capsule orally once daily for 16 weeks.</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="216"/>
            <count group_id="B2" value="224"/>
            <count group_id="B3" value="222"/>
            <count group_id="B4" value="662"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="123"/>
                    <measurement group_id="B2" value="132"/>
                    <measurement group_id="B3" value="133"/>
                    <measurement group_id="B4" value="388"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="93"/>
                    <measurement group_id="B2" value="92"/>
                    <measurement group_id="B3" value="89"/>
                    <measurement group_id="B4" value="274"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="19.6" spread="7.70"/>
                    <measurement group_id="B2" value="19.6" spread="7.54"/>
                    <measurement group_id="B3" value="18.7" spread="6.34"/>
                    <measurement group_id="B4" value="19.3" spread="7.21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="115"/>
                    <measurement group_id="B2" value="121"/>
                    <measurement group_id="B3" value="115"/>
                    <measurement group_id="B4" value="351"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="101"/>
                    <measurement group_id="B2" value="103"/>
                    <measurement group_id="B3" value="107"/>
                    <measurement group_id="B4" value="311"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="35"/>
                    <measurement group_id="B2" value="30"/>
                    <measurement group_id="B3" value="37"/>
                    <measurement group_id="B4" value="102"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="181"/>
                    <measurement group_id="B2" value="194"/>
                    <measurement group_id="B3" value="185"/>
                    <measurement group_id="B4" value="560"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="7"/>
                    <measurement group_id="B4" value="18"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="47"/>
                    <measurement group_id="B2" value="49"/>
                    <measurement group_id="B3" value="40"/>
                    <measurement group_id="B4" value="136"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="159"/>
                    <measurement group_id="B2" value="163"/>
                    <measurement group_id="B3" value="170"/>
                    <measurement group_id="B4" value="492"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="5"/>
                    <measurement group_id="B4" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="216"/>
                    <measurement group_id="B2" value="224"/>
                    <measurement group_id="B3" value="222"/>
                    <measurement group_id="B4" value="662"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Inflammatory Lesion Counts to Week 16 (Last Observation Carried Forward [LOCF])</title>
        <description>The Inflammatory lesion count was the count of papules and pustules: papule was a small, solid elevation less than 0.5 cm in diameter, pustule was a small, circumscribed elevation of the skin that contains yellow-white exudate. Change from baseline in inflammatory lesion counts to Week 16 (LOCF) were reported.</description>
        <time_frame>From Baseline up to Week 16 (LOCF)</time_frame>
        <population>Intent To Treat (ITT) population consisted of all participants who were randomized and to whom study drug was dispensed.</population>
        <group_list>
          <group group_id="O1">
            <title>CD2475/101 40 mg</title>
            <description>Participants received 40 mg of CD2475/101 oral tablet plus placebo capsule orally once daily for 16 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Doxycycline 100 mg</title>
            <description>Participants received 100 mg of Doxycycline capsule plus placebo tablet orally once daily for 16 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Participants received matching placebo tablet plus placebo capsule orally once daily for 16 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Inflammatory Lesion Counts to Week 16 (Last Observation Carried Forward [LOCF])</title>
          <description>The Inflammatory lesion count was the count of papules and pustules: papule was a small, solid elevation less than 0.5 cm in diameter, pustule was a small, circumscribed elevation of the skin that contains yellow-white exudate. Change from baseline in inflammatory lesion counts to Week 16 (LOCF) were reported.</description>
          <population>Intent To Treat (ITT) population consisted of all participants who were randomized and to whom study drug was dispensed.</population>
          <units>lesion count</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="216"/>
                <count group_id="O2" value="224"/>
                <count group_id="O3" value="222"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-16.1" spread="11.39"/>
                    <measurement group_id="O2" value="-12.9" spread="14.60"/>
                    <measurement group_id="O3" value="-12.6" spread="16.44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.006</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-3.6</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-6.1</ci_lower_limit>
            <ci_upper_limit>-1.1</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.024</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-2.9</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-5.4</ci_lower_limit>
            <ci_upper_limit>-0.4</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.595</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.7</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3.2</ci_lower_limit>
            <ci_upper_limit>1.8</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Investigator Global Assessment (IGA) Success Rate at Week 16 (Last Observation Carried Forward [LOCF])</title>
        <description>IGA scale consisted of 5 grades (0-4) among which 0= Clear (no evidence of papules or pustules [inflammatory lesions]), 1= Almost clear (rare non-inflamed papules (papules must be resolving and hyperpigmented, though not pink-red), 2= Mild (few inflammatory lesions [papules/pustules only; no nodulo-cystic lesions]), 3=Moderate (multiple inflammatory lesions evident: many papules/pustules; up to two nodulocystic lesions), 4= Severe (inflammatory lesions are more apparent, many papules/pustules, few nodulo-cystic lesions). Success rate was defined as percentage of participants who achieved an Investigator Global Assessment (IGA) score of 1 (almost clear) or 0 (Clear) and at least a 2-grade improvement from Baseline to Week 16 (LOCF).</description>
        <time_frame>Week 16 (LOCF)</time_frame>
        <population>ITT Population consisted of all participants who were randomized and to whom study drug was dispensed.</population>
        <group_list>
          <group group_id="O1">
            <title>CD2475/101 40 mg</title>
            <description>Participants received 40 mg of CD2475/101 oral tablet plus placebo capsule orally once daily for 16 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Doxycycline 100 mg</title>
            <description>Participants received 100 mg of Doxycycline capsule plus placebo tablet orally once daily for 16 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Participants received matching placebo tablet plus placebo capsule orally once daily for 16 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Investigator Global Assessment (IGA) Success Rate at Week 16 (Last Observation Carried Forward [LOCF])</title>
          <description>IGA scale consisted of 5 grades (0-4) among which 0= Clear (no evidence of papules or pustules [inflammatory lesions]), 1= Almost clear (rare non-inflamed papules (papules must be resolving and hyperpigmented, though not pink-red), 2= Mild (few inflammatory lesions [papules/pustules only; no nodulo-cystic lesions]), 3=Moderate (multiple inflammatory lesions evident: many papules/pustules; up to two nodulocystic lesions), 4= Severe (inflammatory lesions are more apparent, many papules/pustules, few nodulo-cystic lesions). Success rate was defined as percentage of participants who achieved an Investigator Global Assessment (IGA) score of 1 (almost clear) or 0 (Clear) and at least a 2-grade improvement from Baseline to Week 16 (LOCF).</description>
          <population>ITT Population consisted of all participants who were randomized and to whom study drug was dispensed.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="216"/>
                <count group_id="O2" value="224"/>
                <count group_id="O3" value="222"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.4"/>
                    <measurement group_id="O2" value="13.8"/>
                    <measurement group_id="O3" value="7.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline in Inflammatory Lesion Counts to Week 16 (Last Observation Carried Forward [LOCF])</title>
        <description>The Inflammatory lesion count was the count of papules and pustules: papule was a small, solid elevation less than 0.5 cm in diameter, pustule was a small, circumscribed elevation of the skin that contains yellow-white exudate. Percent change from baseline in inflammatory lesion counts to Week 16 (LOCF) were reported.</description>
        <time_frame>From Baseline up to Week 16 (LOCF)</time_frame>
        <population>ITT population consisted of all participants who were randomized and to whom study drug was dispensed.</population>
        <group_list>
          <group group_id="O1">
            <title>CD2475/101 40 mg</title>
            <description>Participants received 40 mg of CD2475/101 oral tablet plus placebo capsule orally once daily for 16 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Doxycycline 100 mg</title>
            <description>Participants received 100 mg of Doxycycline capsule plus placebo tablet orally once daily for 16 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Participants received matching placebo tablet plus placebo capsule orally once daily for 16 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline in Inflammatory Lesion Counts to Week 16 (Last Observation Carried Forward [LOCF])</title>
          <description>The Inflammatory lesion count was the count of papules and pustules: papule was a small, solid elevation less than 0.5 cm in diameter, pustule was a small, circumscribed elevation of the skin that contains yellow-white exudate. Percent change from baseline in inflammatory lesion counts to Week 16 (LOCF) were reported.</description>
          <population>ITT population consisted of all participants who were randomized and to whom study drug was dispensed.</population>
          <units>percent change</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="216"/>
                <count group_id="O2" value="224"/>
                <count group_id="O3" value="222"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-48.6" spread="31.72"/>
                    <measurement group_id="O2" value="-40.3" spread="40.90"/>
                    <measurement group_id="O3" value="-37.1" spread="44.45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline in Total Lesion Counts to Week 16 (Last Observation Carried Forward [LOCF])</title>
        <description>Total lesions were the sum of inflammatory lesion counts, non-inflammatory lesion counts, nodules and cysts. Percentage change from baseline in total lesion counts to Week 16 were reported.</description>
        <time_frame>From Baseline up to Week 16 (LOCF)</time_frame>
        <population>ITT population consisted of all participants who were randomized and to whom study drug was dispensed.</population>
        <group_list>
          <group group_id="O1">
            <title>CD2475/101 40 mg</title>
            <description>Participants received 40 mg of CD2475/101 oral tablet plus placebo capsule orally once daily for 16 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Doxycycline 100 mg</title>
            <description>Participants received 100 mg of Doxycycline capsule plus placebo tablet orally once daily for 16 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Participants received matching placebo tablet plus placebo capsule orally once daily for 16 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline in Total Lesion Counts to Week 16 (Last Observation Carried Forward [LOCF])</title>
          <description>Total lesions were the sum of inflammatory lesion counts, non-inflammatory lesion counts, nodules and cysts. Percentage change from baseline in total lesion counts to Week 16 were reported.</description>
          <population>ITT population consisted of all participants who were randomized and to whom study drug was dispensed.</population>
          <units>percent change</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="216"/>
                <count group_id="O2" value="224"/>
                <count group_id="O3" value="222"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-38.3" spread="32.24"/>
                    <measurement group_id="O2" value="-27.8" spread="43.94"/>
                    <measurement group_id="O3" value="-27.8" spread="38.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Non-Inflammatory Lesion Counts to Week 16 (Last Observation Carried Forward [LOCF])</title>
        <description>The non-inflammatory lesion count was the count of open and closed comedones: Open comedone was a pigmented dilated pilosebaceous orifice (blackhead). Closed comedone was a tiny white papule (whitehead). Change from baseline in non-inflammatory lesion counts to week 16 were reported</description>
        <time_frame>From Baseline up to Week 16 (LOCF)</time_frame>
        <population>ITT population consisted of all participants who were randomized and to whom study drug was dispensed.</population>
        <group_list>
          <group group_id="O1">
            <title>CD2475/101 40 mg</title>
            <description>Participants received 40 mg of CD2475/101 oral tablet plus placebo capsule orally once daily for 16 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Doxycycline 100 mg</title>
            <description>Participants received 100 mg of Doxycycline capsule plus placebo tablet orally once daily for 16 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Participants received matching placebo tablet plus placebo capsule orally once daily for 16 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Non-Inflammatory Lesion Counts to Week 16 (Last Observation Carried Forward [LOCF])</title>
          <description>The non-inflammatory lesion count was the count of open and closed comedones: Open comedone was a pigmented dilated pilosebaceous orifice (blackhead). Closed comedone was a tiny white papule (whitehead). Change from baseline in non-inflammatory lesion counts to week 16 were reported</description>
          <population>ITT population consisted of all participants who were randomized and to whom study drug was dispensed.</population>
          <units>lesion count</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="216"/>
                <count group_id="O2" value="224"/>
                <count group_id="O3" value="222"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-10.0" spread="21.49"/>
                    <measurement group_id="O2" value="-5.2" spread="21.60"/>
                    <measurement group_id="O3" value="-5.8" spread="18.19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Global Assessment for Inflammatory Lesions of Truncal Acne at Baseline, Week 12, and Week 16</title>
        <description>Global assessments for inflammatory lesions of truncal acne were done separately on back and chest. The global assessments severity scale included 5 grades (0-4): where in 0= Clear-no evidence of papules or pustules (inflammatory lesions), 1= Almost clear- rare non-inflamed papules (papules must be resolving and may be hyperpigmented, though not pink-red), 2=Mild- few inflammatory lesions (papules/pustules only; no nodulo-cystic lesions), 3=Moderate- multiple inflammatory lesions evident: many papules/pustules; may be a few nodulocystic lesions, 4=Severe- inflammatory lesions are more apparent, many papules/pustules, may be a few nodulo-cystic lesions.</description>
        <time_frame>Baseline, Week 12, and Week 16</time_frame>
        <population>ITT population consisted of all participants who were randomized and to whom study drug was dispensed.</population>
        <group_list>
          <group group_id="O1">
            <title>CD2475/101 40 mg</title>
            <description>Participants received 40 mg of CD2475/101 oral tablet plus placebo capsule orally once daily for 16 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Doxycycline 100 mg</title>
            <description>Participants received 100 mg of Doxycycline capsule plus placebo tablet orally once daily for 16 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Participants received matching placebo tablet plus placebo capsule orally once daily for 16 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Global Assessment for Inflammatory Lesions of Truncal Acne at Baseline, Week 12, and Week 16</title>
          <description>Global assessments for inflammatory lesions of truncal acne were done separately on back and chest. The global assessments severity scale included 5 grades (0-4): where in 0= Clear-no evidence of papules or pustules (inflammatory lesions), 1= Almost clear- rare non-inflamed papules (papules must be resolving and may be hyperpigmented, though not pink-red), 2=Mild- few inflammatory lesions (papules/pustules only; no nodulo-cystic lesions), 3=Moderate- multiple inflammatory lesions evident: many papules/pustules; may be a few nodulocystic lesions, 4=Severe- inflammatory lesions are more apparent, many papules/pustules, may be a few nodulo-cystic lesions.</description>
          <population>ITT population consisted of all participants who were randomized and to whom study drug was dispensed.</population>
          <units>Units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="216"/>
                <count group_id="O2" value="224"/>
                <count group_id="O3" value="222"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline : Lesion of Truncal Acne on Back</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.6" spread="1.10"/>
                    <measurement group_id="O2" value="1.5" spread="1.09"/>
                    <measurement group_id="O3" value="1.5" spread="1.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline : Lesion of Truncal Acne on Chest</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.2" spread="1.04"/>
                    <measurement group_id="O2" value="1.2" spread="1.00"/>
                    <measurement group_id="O3" value="1.1" spread="0.98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12 : Lesions of Truncal Acne on Back</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.2" spread="1.06"/>
                    <measurement group_id="O2" value="1.1" spread="1.05"/>
                    <measurement group_id="O3" value="1.2" spread="1.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12 : Lesion of Truncal Acne on Chest</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.9" spread="0.94"/>
                    <measurement group_id="O2" value="0.9" spread="0.99"/>
                    <measurement group_id="O3" value="0.9" spread="0.95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16 : Lesions of Truncal Acne on Back</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.1" spread="1.06"/>
                    <measurement group_id="O2" value="1.0" spread="1.06"/>
                    <measurement group_id="O3" value="1.2" spread="1.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16 : Lesion of Truncal Acne on Chest</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.9" spread="1.01"/>
                    <measurement group_id="O2" value="0.8" spread="0.93"/>
                    <measurement group_id="O3" value="0.9" spread="0.95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With at Least One Adverse Event (AE)</title>
        <description>An AE was any untoward medical occurrence in a participant or clinical investigation participants administered a pharmaceutical product and which does not necessarily have a causal relationship with this treatment. Number of participants with at least one AE were reported.</description>
        <time_frame>From Baseline up to Week 16</time_frame>
        <population>Safety Population consisted of all participants who received at least one dose of study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>CD2475/101 40 mg</title>
            <description>Participants received 40 mg of CD2475/101 oral tablet plus placebo capsule orally once daily for 16 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Doxycycline 100 mg</title>
            <description>Participants received 100 mg of Doxycycline capsule plus placebo tablet orally once daily for 16 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Participants received matching placebo tablet plus placebo capsule orally once daily for 16 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With at Least One Adverse Event (AE)</title>
          <description>An AE was any untoward medical occurrence in a participant or clinical investigation participants administered a pharmaceutical product and which does not necessarily have a causal relationship with this treatment. Number of participants with at least one AE were reported.</description>
          <population>Safety Population consisted of all participants who received at least one dose of study drug.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="216"/>
                <count group_id="O2" value="223"/>
                <count group_id="O3" value="222"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="63"/>
                    <measurement group_id="O2" value="83"/>
                    <measurement group_id="O3" value="89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>From Baseline up to Week 16</time_frame>
      <group_list>
        <group group_id="E1">
          <title>CD2475/101 40 mg</title>
          <description>Participants received 40 mg of CD2475/101 oral tablet plus placebo capsule orally once daily for 16 weeks.</description>
        </group>
        <group group_id="E2">
          <title>Doxycycline 100 mg</title>
          <description>Participants received 100 mg of Doxycycline capsule plus placebo tablet orally once daily for 16 weeks.</description>
        </group>
        <group group_id="E3">
          <title>Placebo</title>
          <description>Participants received 100 mg of Doxycycline capsule plus placebo tablet orally once daily for 16 weeks.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (13.0)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="216"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="222"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="216"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="223"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="222"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Coagulopathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="216"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="222"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Forearm fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="216"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="223"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="222"/>
              </event>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="216"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="223"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="222"/>
              </event>
              <event>
                <sub_title>Multiple drug overdose intentional</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="216"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="222"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Uterine leiomyoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="216"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="223"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="222"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Multiple sclerosis relapse</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="216"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="222"/>
              </event>
              <event>
                <sub_title>Hepatic encephalopathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="216"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="222"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Affective disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="216"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="222"/>
              </event>
              <event>
                <sub_title>Suicide attempt</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="216"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="222"/>
              </event>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="216"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="223"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="222"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Urticaria</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="216"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="223"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="222"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA (13.0)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="29" subjects_at_risk="216"/>
                <counts group_id="E2" subjects_affected="51" subjects_at_risk="223"/>
                <counts group_id="E3" subjects_affected="29" subjects_at_risk="222"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="216"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="223"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="222"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="216"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="223"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="222"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="216"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="223"/>
                <counts group_id="E3" subjects_affected="14" subjects_at_risk="222"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="216"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="223"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="222"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There IS an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Clinical Operations</name_or_title>
      <organization>Galderma</organization>
      <phone>817 961 5000 ext +1</phone>
      <email>Clinical.Studies@galderma.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

